Glucocorticosteroids (GCS) have been used successfully in the treatment of
inflammatory conditions such as asthma and acute graft-vs-host disease, but
their mode of action remains unclear. There have been numerous reports of
the in-vitro suppression of cytokine production by GCS based on quantitatio
n of cytokines by ELISA on bull; supernatants from isolated cell culture sy
stems. We report the use of a whole-blood intracellular cytokine assay whic
h is more representative of an in-vivo environment. We examined the effects
of GCS, prednisolone and dexamethasone, on cytokine production by individu
al cells (monocytes, T lymphocytes and natural killer or NK cells) in heter
ogenous cell populations. Cells in whole blood were activated with various
stimuli: phorbol ester and calcium ionophore for T cells, Escherichia coli
lipopolysaccharide (LPS) for monocytes, and phytohaemagglutinin (PHA) plus
interleukin (IL)-12 for NK cells. Brefeldin A was used as an intracellular
transport inhibitor to enhance the detection of intracellular cytokine prod
uction. The effects of various concentrations (10(-5), 10(-7), 10(-9) and 1
0(-11) M) of GCS on cytokine production were studied using multiparameter f
low cytometry. After surface staining with fluorescently conjugated monoclo
nal antibodies (MoAbs) to identify cell type, cells were fixed and permeabi
lised. Intracellular cytokines interferon (IFN)-gamma, IL-10, IL-1 alpha an
d beta, IL-2, tumour necrosis factor (TNF)-alpha, and IL-12 were stained wi
th their respective conjugated MoAbs. The GCS both caused a dose-dependent
modulation of cytokine production by T cells, monocytes and NK cells. After
4 h, a decrease in the MFI (amount of cytokine produced per cell) was note
d for all cell types. After 24 h a decrease in both MFI and the percentage
of cells producing cytokine was observed for all cell types. The exception
was monocyte production of IL-10 which was enhanced at low concentrations o
f GCS (10(-9) and 10(-11) M). Our findings thus suggest that one anti-infla
mmatory mechanism of GCS action may be through inhibition of the release of
pro-inflammatory cytokines IL-1 alpha and beta, IL-2, IFN-gamma and TNF-al
pha, and up-regulation of the anti-inflammatory cytokine IL-10.